Article Text

PDF
P156 Efficacy, safety and tolerability of once-daily tiotropium respimat® add-on therapy in children with moderate symptomatic asthma

Abstract

O Schmidt has received research grants from Boehringer Ingelheim;

E Hamelmann has received research grants and other fees from Boehringer Ingelheim and non-financial support from Boehringer Ingelheim;

C Vogelberg has participated in an advisory board for Boehringer Ingelheim;

I Laki has nothing to disclose;

G El Azzi is an employee of Boehringer Ingelheim;

M Engel is an employee of Boehringer Ingelheim;

P Moroni-Zentgraf is an employee of Boehringer Ingelheim;

H Finnigan is an employee of Boehringer Ingelheim;

M Vandewalker has received research grants and personal fees from Boehringer Ingelheim.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.